Targeted Therapeutic Strategies for Fetal Hemoglobin Induction
|
|
- Steven Arthur Sullivan
- 5 years ago
- Views:
Transcription
1 STRATEGIES FOR OPTIMAL MANAGEMENT IN THALASSEMIA -NOW AND IN THE FUTURE Targeted Therapeutic Strategies for Fetal Hemoglobin Induction Vijay G. Sankaran Children s Hospital Boston, Harvard Medical School, Boston, MA; 2 Whitehead Institute for Biomedical Research, Cambridge, MA; and 3 Broad Institute, Cambridge, MA Increased levels of fetal hemoglobin (HbF) can ameliorate the severity of the -hemoglobin disorders, sickle cell disease (SCD) and -thalassemia, which are major sources of morbidity and mortality worldwide. As a result, there has been a longstanding interest in developing therapeutic approaches for inducing HbF. For more than 3 decades, the majority of HbF inducers developed were based on empiric observations and have had limited success. Recently, human genetic approaches have provided insight into previously unappreciated regulators of the fetal-to-adult hemoglobin switch and HbF silencing, revealing molecular targets to induce HbF. This article reviews these developments and discusses how molecules including BCL11A, KLF1, MYB, SOX6, mirnas 15a and 16-1, and histone deacetylase 1 and 2 (HDAC1/2) could be important targets for HbF induction in humans. The current understanding of how these molecules function and the benefits and drawbacks of each of these potential therapeutic targets are also examined. The identification of these regulators of HbF expression is extremely promising and suggests that rationally designed approaches targeting the very mechanisms mediating this switching process could lead to better, less toxic, and more effective strategies for HbF induction. Introduction The -hemoglobin disorders, sickle cell disease (SCD) and thalassemia, are major causes of morbidity and mortality worldwide, 1 as the most common genetic disorders in the world. With the epidemiological transition that many developing countries are undergoing, resulting in significant decreases in mortality from infectious and nutritional causes, there will likely be an increase in the prevalence of these diseases in the ensuing years. In SCD, a single base substitution causes a missense mutation of a valine for glutamic acid at amino acid 6 of the -globin protein chain, which leads to a propensity of the sickle hemoglobin to polymerize. This results in deformation of RBCs containing this hemoglobin, which can block small blood vessels, leading to impaired oxygen delivery to tissues. This can cause significant pain crises, respiratory complications, and organ damage. In -thalassemia, insufficient production of the -globin molecule results in an excess of unpaired -globin chains that can precipitate within erythroid precursors. The precipitation of these free -globin chains impairs the maturation of these precursors, leading to their death and thereby causing ineffective production of RBCs. Significant anemia results and the consequent expansion of erythroid precursors can lead to secondary problems in bones and other organs. Whereas the only cures for these disorders involve BM transplantation 2 and gene or cellular therapy, 3 there are numerous challenges associated with these treatments and therefore they have significant limitations for widespread use, particularly in the developing world. 4 These curative therapies still remain largely experimental, although important advances in these approaches are being made. 5 Currently, the major treatment for SCD and -thalassemia involves symptomatic care and transfusion of RBCs as clinically necessary. However, the use of regular transfusion therapy can lead to significant problems, particularly iron overload, which can even occur when the strictest iron-chelation regimens are used. 6 Treating the -hemoglobinopathies through HbF induction A series of important natural observations demonstrated that the severity of SCD and -thalassemia could be ameliorated via increased production of fetal hemoglobin (HbF), which is composed of the -like globin chain, -globin, and the adult -globin molecule. In normal infants, the predominant -like globin before birth is -globin, and there is a switch to adult -globin expression in the months after birth, a process known as the fetal-to-adult hemoglobin switch (Figure 1). 7,8 Children with SCD were noted to be asymptomatic until after infancy, which was postulated to be attributable to elevated HbF levels. 9 This notion was substantiated by observations of patients with compound heterozygosity for SCD and hereditary persistence of HbF mutations, who were largely asymptomatic. 10 Moreover, certain populations of patients with SCD, such as those from parts of Saudi Arabia and India, had unusually high levels of HbF associated with a less symptomatic clinical course These observations were confirmed with larger epidemiological studies showing that increased HbF levels can significantly ameliorate the clinical severity of SCD Similar observations were made in patients with -thalassemia. Clinical observations in rare -thalassemia patients with highly elevated levels of HbF showed that these increased levels resulted in a milder clinical course, and infants with -thalassemia only begin to show symptoms after the expression of HbF declines in the months after birth. 10,16 Larger epidemiological studies of thalassemia populations have confirmed these findings The human globin genes were among the first genes to be cloned, and soon thereafter the structure of the entire -globin cluster was mapped and sequenced. Around this time, it was observed that the silenced -globin genes in the -globin cluster underwent DNA methylation in adult erythroid cells, whereas this was not the case in erythroid cells from embryonic life. 4 Given these observations, Hematology
2 Figure 1. Molecular regulation of the fetal-to-adult hemoglobin switch. The human -globin gene locus, which is located on chromosome 11, has a series of 5 genes that are developmentally expressed at distinct stages of human ontogeny (panel A bottom). The -globin gene is restricted to the transiently expressed embryonic primitive lineage of RBC produced in the first several weeks of gestation. The -globin genes encode the genes that uniquely form HbF, which is the predominant hemoglobin during the course of gestation. There is a switch to expression of the adult -globin gene around the time of birth (B). B-cell lymphoma/leukemia 11A (BCL11A) and its protein partners, including GATA binding protein 1 (GATA1), zinc finger protein multi-type 1 (ZFPM1 or FOG1), and the nucleosome remodeling and deacetylase (NuRD) complex, bind to sequences within the globin locus (panel A tan ovals) and repress the expression of the -globin genes. Krüppel-like factor 1 (KLF1) interacts with this process by positively regulating the expression of BCL11A (green arrow in panel A) and also by directly binding to and promoting transcription of the adult -globin gene. It is unknown whether KLF1 affects HbF expression through more global effects on erythropoiesis (panel A top), which may also be targeted by other factors associated with HbF (eg, MYB). HSs indicates DNase I hypersensitive sites; LCR, locus control region. (Reprinted with permission from Sankaran and Nathan. 7 ) preclinical trials in primates of the DNA-hypomethylating agent 5-azacytidine were subsequently performed and demonstrated success at inducing HbF. 4,20 This approach was then tested in patients with -thalassemia and SCD. 21 However, there was concern over the long-term consequences of a potentially mutagenic compound such as 5-azacytidine. Around this time, it was suggested that the effect of 5-azacytidine on HbF induction might relate, at least in part, to its ability to act as an S-phase cell-cycle inhibitor, rather than through alteration of DNA methylation at the -globin gene promoters. 4 Studies in primates demonstrated that numerous S-phase inhibitors, including hydroxyurea, were all highly effective as inducers of HbF. This then led to small clinical trials of 460 American Society of Hematology
3 hydroxyurea, which had the safest side-effect profile, in SCD patients in whom a robust HbF inductive response was demonstrated. 22 The use of hydroxyurea was then examined in larger clinical trials that led to its US Food and Drug Administration approval for use in adult patients with SCD. 23,24 Unfortunately, hydroxyurea is only effective to some extent in a subset of patients with SCD. There has also been limited success with the use of hydroxyurea in -thalassemia, which may be attributable to the requirement for much more HbF to achieve globin chain balance in this disease and to the inability to escalate hydroxyurea dosing as a result of cytopenias. In the mid-1980s, it was shown that infants of diabetic mothers have a delayed fetal-to-adult hemoglobin switch. 25,26 Because it was known that hydroxybutyrate is elevated in these diabetic mothers, a series of experiments was performed to determine whether butyrate or other similar short-chain fatty acids may be effective as inducers of HbF. Whereas initial trials showed promise, 27,28 these therapies were not widely effective in larger clinical trials. 4,29 It should be noted nonetheless that a subset of patients did show responses in these trials. 4,29 However, additional concerns were raised over possible toxic effects and the difficulty in delivery of these medications, which limited further clinical trials and drugdevelopment efforts. It has been suggested that these short-chain fatty acids are likely to induce HbF through the inhibition of histone deacetylases (HDACs). 30 A variety of HDAC inhibitors can be potent inducers of HbF in vitro, and so it is possible that these compounds may show clinical efficacy in vivo. 31,32 Identifying molecular targets for HbF induction Molecules that regulate the fetal-to-adult hemoglobin switch and help to maintain HbF silencing in humans have been long sought given the possibility of using this information to develop targeted therapeutic approaches for HbF induction. 7,32 Whereas numerous regulators of erythropoiesis and globin gene regulation had been identified, none of the previously examined molecules appeared to be specific regulators of the fetal-to-adult switch. Recent insight into this process has come from studies using human genetic approaches. By taking advantage of natural variation in HbF levels in humans, genome-wide association (GWA) studies were performed to find common genetic variants associated with variations in HbF levels. The initial GWA studies of HbF were performed in nonanemic individuals. Two separate studies were performed around the same time and showed association of variants at 3 major genomic loci with HbF levels. 33,34 This included the -globin locus on chromosome 11, a region between the genes HBS1L and MYB on chromosome 6, and a region within the BCL11A gene on chromosome 2. These findings were replicated in patients with SCD and -thalassemia, and the ameliorating effect of these loci upon these diseases was also demonstrated in multiple other studies. 18,19,33,35 Regulation of HbF expression by BCL11A and SOX6 The role of BCL11A was described previously for B-lymphocyte production, but no studies had explored whether this gene had a role in erythropoiesis. As a result, the role of this gene in human globin gene regulation and erythropoiesis was assessed soon after the initial association studies. 36 BCL11A protein levels appeared to be correlated with the developmental stage of expression, such that primitive and fetal liver erythroid cells that expressed high levels of -globin had low or absent expression of the full-length forms of BCL11A, whereas shorter variant forms of the protein were noted in these cells. This result suggested that this gene product may act as a repressor of the -globin genes. To directly test this, knock-down of BCL11A using sirna approaches was performed in primary adult erythroid progenitors, and -globin expression could be induced. The degree of -globin induction appeared to be linearly related to the extent of knock-down of BCL11A. Interestingly, major perturbations in erythropoiesis did not appear to occur despite the robust -globin induction seen. Follow-up studies have demonstrated similar results when knocking down the expression of BCL11A using sirnas It was also shown that BCL11A directly interacts with chromatin at the human -globin locus in primary erythroid cells and that it appeared to act as part of a complex with the transcription factor GATA-1 and the NuRD chromatin remodeling and repressor complex (Figure 1). 36 The NuRD complex includes HDAC1 and HDAC2, which have been suggested to be the critical HDACs necessary for HbF silencing (Table 1). 40 Whereas hemoglobin switching in mouse models, even those harboring a human -globin locus transgene, appears to diverge from the normal ontogeny of globin expression seen in humans, an evolutionarily conserved role of BCL11A in globin gene silencing and switching was demonstrated in mice. 41 Specifically, transgenic mice with the human -globin locus express the -globin gene in a manner similar to the endogenous mouse embryonic globin genes, although there is some variation in the expression between these globin genes. 42 Mice lacking BCL11A appear to have normal erythropoiesis, but fail to silence the embryonic globin genes in definitive erythroid cells, allowing persistent expression of -globin when the intact human -globin locus is present. 41 This study reinforces the importance of BCL11A as a critical mediator of globin switching in mammals. The exact mechanism by which BCL11A silences -globin expression remains unclear. A recent study suggests that this may be mediated through both interactions with transcription factors such as SOX6 that bind chromatin at the proximal -globin promoters and through long-range interactions with a variety of regions throughout the -globin gene cluster. 43 When BCL11A is absent, the conformation of the -globin locus changes such that the upstream enhancer known as the locus control region is juxtaposed with the transcriptionally activated -globin genes. A similar phenomenon occurs when cells are treated with HDAC inhibitors that induce -globin gene expression. 40 However, it is unclear whether these conformational alterations are directly mediated by BCL11A or if they occur secondary to the HbF-inductive effect of BCL11A (or HDAC) inhibition. Nonetheless, these findings strongly support the notion that BCL11A has a direct role in silencing -globin expression within the -globin locus. Therefore, BCL11A is likely to be an important therapeutic target. The fact that it can induce HbF without resulting in a major perturbation in erythropoiesis is very promising, although it is known to have important effects in other lineages such as B lymphocytes, stressing the importance of in vivo modeling and analysis as part of ongoing efforts to target BCL11A for HbF induction (Table 1). Strategies aimed at targeting BCL11A may rely on altering its expression level or activity. SOX6 may also be a potentially promising target for HbF induction, 43 although it is known to be necessary for normal erythropoiesis (Table 1). 44 Interestingly, however, a patient has been reported with a heterozygous disruption of SOX6 who did not have elevated HbF levels, suggesting that the SOX6 gene may have a mechanism for dosage compensation or that there may be a particular threshold necessary for reducing the expression of this gene to have robust HbF induction. 45 Hematology
4 Table 1. A sampling of molecular targets for HbF induction Target Target alterations for HbF induction Benefits Drawbacks/limitations BCL11A 2 Robust HbF induction seen in a variety of experimental settings with no perturbation of erythropoiesis Robust effects of putative regulatory common genetic variants on clinical severity in hemoglobinopathies SOX6 2 HbF induction seen after knock-down in primary human cells KLF1 2 Specific to the erythroid lineage Supported by humans with heterozygous mutations and elevated HbF levels MYB 2 Relative specificity in hematopoiesis Robust effects of putative regulatory common genetic variants on clinical severity in hemoglobinopathies mirna-15a/ Patients with trisomy 13 have elevations of HbF levels and increased expression of these mirnas without other perturbations in erythropoiesis HDAC1/2 2 Robust drugs targeting these molecules are already available and in clinical trials Newer HDAC inhibitors can be very specific Required in B lymphocytes and other cell types, so toxicity or untoward effects of targeting approaches in vivo may be seen May affect erythropoiesis and be necessary in other cell types Heterozygous mutation in patient occurs without HbF elevation Knock-down may affect erythropoiesis Variable phenotype in humans with heterozygous mutations Interfering with expression or function may affect erythropoiesis Limited mechanistic knowledge of function in globin gene regulation Limited knowledge of the physiological role of these mirnas in erythropoiesis and other cell types mirnas target a variety of molecules, which may lead to unpredictable side effects These HDACs play a wide variety of roles in a number of tissues and toxicity could be a major problem before HbF-inductive effects are seen Silencing of HbF by KLF1 Using independent and complementary approaches, two studies have demonstrated that the expression of BCL11A appears to be controlled by the erythroid-specific transcription factor KLF1. In one study, a mouse with a hypomorphic allele of KLF1 had elevations of embryonic globin expression, and transgenic mice with the human -globin locus showed persistent expression of -globin. 39 As a result, the investigators used sirna approach to find out whether the same regulation could occur in primary human erythroid cells and demonstrate a similar connection. They were able to demonstrate that this effect occurs through both direct effects of KLF1 at the -globin locus, but also via indirect effects mediated through reduced expression of BCL11A upon KLF1 knock-down. This finding demonstrated that KLF1 was a direct positive transcriptional regulator of BCL11A expression. A different study examined the genetic basis of an unlinked form of hereditary persistence of HbF that was found to be due to a KLF1 missense mutation in this family. 38 Using primary cells from these patients and from unaffected controls, the investigators of that study were able to demonstrate that the effect seen was in part attributable to a silencing effect of KLF1 on BCL11A. One area of ongoing uncertainty relates to the human phenotypes seen in various cases of KLF1 mutations. Whereas in the initial report, all recipients of the missense mutation had elevations in HbF expression, it should be noted that this actually varied between 3% and 19% of total hemoglobin levels. 7 In addition, other reports of heterozygous KLF1 mutations in humans either show concomitant disruption of erythropoiesis or little effect on HbF expression. 46,47 The basis of this variation remains to be determined and will be important to better understand the mechanisms by which KLF1 acts, both directly and indirectly, to affect HbF expression (Figure 1). This will be critical for any future work attempting to target KLF1 for HbF induction, particularly if the untoward effects of such inhibition on erythroid differentiation are to be avoided. However, given the specificity of KLF1 within the erythroid lineage, and if disruption of erythropoiesis could be avoided while allowing for HbF expression, it may be a very promising therapeutic target to induce HbF (Table 1). The role of MYB and mirnas 15a/16-1 in HbF regulation The GWA studies also demonstrated strong associations of variants in the intergenic region between the genes HBS1L and MYB with HbF levels. The exact mechanism by which these variants result in elevated HbF levels has remained unclear, although it has been suggested that this may occur through an effect on the expression or function of MYB. 7,48 Overexpression of MYB in K562 cells reduced -globin expression, and primary erythroid cultures with higher HbF expression had lower levels of MYB expression. 49 More direct evidence lending further support to a connection between MYB and HbF expression has recently been reported. Following up on a classic clinical observation that patients with a trisomy of chromosome 13 have elevations of HbF, and using partial trisomy cases to map this trait, it was shown that a gene in 13q14 appears to be responsible for mediating this effect. 50 Using an integrative genomic approach, 2 co-transcribed mirnas, 15a and 16-1, appeared to be 462 American Society of Hematology
5 top candidates as mediators of this trait. This was supported by the finding that slight overexpression of these mirnas in primary adult erythroid cells could result in elevations of -globin expression. Consistent with prior studies, 51 these mirnas appeared to potently target and down-regulate MYB protein expression. Finally, sirnamediated knock-down of MYB could result in a similar effect, suggesting a direct connection between the effect of these mirnas on HbF silencing and their effect on MYB expression. This finding also supports the idea that the intergenic variants between HBS1L and MYB may act to effect MYB expression. 48 Sequencing of MYB has revealed rare coding variants within this gene that appear to be associated with elevated HbF levels in patients with SCD, providing further support for a role of MYB in modulating HbF expression. 52 Numerous studies have shown that MYB is necessary for normal erythropoiesis, although hypomorphic mouse alleles of this gene have subtle effects on erythropoiesis. 53 Moreover, such in vivo studies demonstrate the specificity of MYB in hematopoietic cell types. If the function of MYB could be partially disrupted and targeted in an erythroid-specific manner, then it may be an attractive therapeutic target (Table 1). The exact physiological role of mirna-15a and mirna-16-1 in erythropoiesis remains to be elucidated; however, it is possible that these mirnas may be attractive targets for HbF induction. Support comes from the finding that trisomy 13 patients have relatively normal erythropoiesis while having persistent HbF expression. 50 Much more work is necessary to elucidate the mechanisms through which these factors affect HbF expression, which will be important in strategies for HbF induction. Other factors involved in HbF regulation In addition to the aforementioned molecules, a few other factors have been suggested to play a role in HbF expression, although support from human genetic studies is not currently present for these other factors. One recent study described the role of the Friend of PRMT1 (FOP1) protein in HbF silencing. 54 Knock-down of this factor in primary human adult erythroid cells resulted in robust elevations of HbF levels. The mechanism through which this factor carries out this activity remains unclear and further work will be necessary to more carefully investigate this observation. In addition, other factors such as the orphan nuclear hormone receptors TR2, TR4, and COUP-TFII have been suggested to play a role in HbF silencing. 8 Further work to examine the role of these factors in HbF regulation will be needed to better understand how these molecules regulate this process. As mentioned above, the HDACs are promising targets and are recruited by and interact with a variety of transcription factors involved in globin gene regulation, such as BCL11A. 8 Other DNAand histone-modifying enzymes have been suggested to play a role in globin gene regulation and thus are worthwhile considerations as possible targets for HbF induction. For example, there is support for a role of the DNA methyltransferase DNMT1 in silencing HbF. 55 Because 5-azacytidine and its derivative, decitabine, which both induce HbF in vivo, target DNMT1, it is possible that future strategies targeting this pathway may lead to more effective therapies. Approaches and future directions Whereas the recent findings described above have uncovered promising molecular targets for therapeutic efforts aimed at HbF induction, a great deal of further work is necessary before these findings can be translated to therapeutic advances. The question of how best to develop such therapies is of great interest in this field. One immediately applicable approach would be to use gene therapeutic approaches to deliver sirnas that target the molecules described above. With the exception of mirnas 15a and 16-1, the other therapeutic targets discussed here all appear to have HbFinductive effects when their expression is reduced (Table 1). Preliminary preclinical findings support such approaches. 37 In addition to or in place of delivery of a nonmutated globin gene, such sirna molecules could be extremely useful. These gene therapy methods are promising and could be targeted to the hematopoietic system alone. Given recent advances in this field, 56 it is possible that such approaches could enter the clinical arena in the near future. Such gene therapy trials that are performed on a relatively small scale may help to reveal which therapeutic targets would be efficacious in vivo for more broadly applicable small-molecule approaches. Another approach would be to introduce exogenous molecules such as zinc-finger transcription factors, which interfere with the normal activity of endogenous molecules found at the -globin locus and thus act to induce HbF. 37 Small molecules would be ideal as therapies in these globally widespread diseases. However, nearly all of the molecular targets that currently exist are transcriptional regulators of globin gene expression (Table 1). These molecules have been notoriously difficult to target, although recent approaches suggest that promising leads could be developed. 57 As enzymes, the HDACs are ideal targets, and many specific inhibitors of HDACs have already been developed. Some of these appear to be promising leads for HbF-inductive therapies and are already in clinical trials for other indications such as cancer. 58 Other small molecules targeting epigenetic enzymes, such as DNMT1, may show possible benefit as HbF inducers and, in many cases, inhibitors of these enzymes are already available or are in development. At the present time, it is difficult to predict which targets may be best, and, given the number of recently identified molecular targets, it is likely that the broadest approaches aimed at targeting as many of these molecules as possible may eventually yield specific candidates that can successfully pass the early stages of evaluation. However, the fact that there are so many recently identified targets lends promise to this field. In addition, the ongoing basic science studies that are aimed at better understanding the mechanisms by which such molecules silence HbF will likely yield additional insights into how this process can best be modulated. Acknowledgments I apologize to those investigators whose work could not be cited here because of space limitations. I am grateful to my mentors who have given me the opportunity to study hemoglobin switching and to the many colleagues I have had the privilege of working with. Disclosures Conflict-of-interest disclosure: The author declares no competing financial interests. Off-label drug use: None disclosed. Correspondence Vijay G. Sankaran, Children s Hospital Boston, 300 Longwood Avenue, Boston, MA 02115; Phone: (617) ; sankaran@broadinstitute.org. References 1. Weatherall D, Akinyanju O, Fucharoen S, Olivieri N, Musgrove P. Inherited Disorders of Hemoglobin. Disease Control Hematology
6 Priorities in Developing Countries. 2nd ed. New York, NY: Oxford University Press; 2006: Michlitsch JG, Walters MC. Recent advances in bone marrow transplantation in hemoglobinopathies. Curr Mol Med. 2008;8: Persons DA. Hematopoietic stem cell gene transfer for the treatment of hemoglobin disorders. Hematology Am Soc Hematol Educ Program. 2009: Sankaran VG, Nathan DG. Thalassemia: an overview of 50 years of clinical research. Hematol Oncol Clin North Am. 2010;24: Hsieh MM, Kang EM, Fitzhugh CD, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med. 2009;361: Porter JB, Shah FT. Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies. Hematol Oncol Clin North Am. 2010;24: Sankaran VG, Nathan DG. Reversing the hemoglobin switch. N Engl J Med. 2010;363: Wilber A, Nienhuis AW, Persons DA. Transcriptional regulation of fetal to adult hemoglobin switching: new therapeutic opportunities. Blood. 2011;117: Watson J. The significance of the paucity of sickle cells in newborn Negro infants. Am J Med Sci. 1948;215: Weatherall DJ, Clegg JB. The Thalassaemia Syndromes. 4th ed. Malden, MA: Blackwell Science; Perrine RP, Brown MJ, Clegg JB, Weatherall DJ, May A. Benign sickle-cell anaemia. Lancet. 1972;2: Kar BC, Satapathy RK, Kulozik AE, et al. Sickle cell disease in Orissa State, India. Lancet. 1986;2: Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330: Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med. 1991;325: Castro O, Brambilla DJ, Thorington B, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood. 1994;84: Weatherall DJ. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nat Rev Genet. 2001;2: Premawardhena A, Fisher CA, Olivieri NF, et al. Haemoglobin E beta thalassaemia in Sri Lanka. Lancet. 2005;366: Galanello R, Sanna S, Perseu L, et al. Amelioration of Sardinian beta0 thalassemia by genetic modifiers. Blood. 2009; 114: Nuinoon M, Makarasara W, Mushiroda T, et al. A genomewide association identified the common genetic variants influence disease severity in beta(0)-thalassemia/hemoglobin E. Hum Genet. 2010;127: DeSimone J, Heller P, Hall L, Zwiers D. 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. Proc Natl Acad Sci U S A. 1982;79: Ley TJ, DeSimone J, Anagnou NP, et al. 5-azacytidine selectively increases gamma-globin synthesis in a patient with beta thalassemia. N Engl J Med. 1982;307: Platt OS, Orkin SH, Dover G, Beardsley GP, Miller B, Nathan DG. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest. 1984;74: Platt OS. Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med. 2008;358: Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332: Perrine SP, Greene MF, Faller DV. Delay in the fetal globin switch in infants of diabetic mothers. N Engl J Med. 1985;312: Bard H, Prosmanne J. Relative rates of fetal hemoglobin and adult hemoglobin synthesis in cord blood of infants of insulindependent diabetic mothers. Pediatrics. 1985;75: Perrine SP, Ginder GD, Faller DV, et al. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the betaglobin disorders. N Engl J Med. 1993;328: Perrine SP, Olivieri NF, Faller DV, Vichinsky EP, Dover GJ, Ginder GD. Butyrate derivatives. New agents for stimulating fetal globin production in the beta-globin disorders. Am J Pediatr Hematol Oncol. 1994;16: Sher GD, Ginder GD, Little J, Yang S, Dover GJ, Olivieri NF. Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies. N Engl J Med. 1995;332: Fathallah H, Weinberg RS, Galperin Y, Sutton M, Atweh GF. Role of epigenetic modifications in normal globin gene regulation and butyrate-mediated induction of fetal hemoglobin. Blood. 2007;110: Cao H, Stamatoyannopoulos G, Jung M. Induction of human gamma globin gene expression by histone deacetylase inhibitors. Blood. 2004;103: Atweh G, Fathallah H. Pharmacologic induction of fetal hemoglobin production. Hematol Oncol Clin North Am. 2010; 24: Uda M, Galanello R, Sanna S, et al. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. Proc Natl Acad Sci U S A. 2008;105: Menzel S, Garner C, Gut I, et al. A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15. Nat Genet. 2007;39: Lettre G, Sankaran VG, Bezerra MA, et al. DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci U S A. 2008;105: Sankaran VG, Menne TF, Xu J, et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science. 2008;322: Wilber A, Hargrove PW, Kim YS, et al. Therapeutic levels of fetal hemoglobin in erythroid progeny of beta-thalassemic CD34 cells after lentiviral vector-mediated gene transfer. Blood. 2011;117: Borg J, Papadopoulos P, Georgitsi M, et al. Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. Nat Genet. 2010;42: Zhou D, Liu K, Sun CW, Pawlik KM, Townes TM. KLF1 regulates BCL11A expression and gamma- to beta-globin gene switching. Nat Genet. 2010;42: Bradner JE, Mak R, Tanguturi SK, et al. Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci USA. 2010;107: Sankaran VG, Xu J, Ragoczy T, et al. Developmental and species-divergent globin switching are driven by BCL11A. Nature. 2009;460: McGrath KE, Frame JM, Fromm GJ, et al. A transient definitive 464 American Society of Hematology
7 erythroid lineage with unique regulation of the beta-globin locus in the mammalian embryo. Blood. 2011;117: Xu J, Sankaran VG, Ni M, et al. Transcriptional silencing of {gamma}-globin by BCL11A involves long-range interactions and cooperation with SOX6. Genes Dev. 2010;24: Dumitriu B, Patrick MR, Petschek JP, et al. Sox6 cellautonomously stimulates erythroid cell survival, proliferation, and terminal maturation and is thereby an important enhancer of definitive erythropoiesis during mouse development. Blood. 2006;108: Sankaran VG, Menne J, Heller R. Heterozygous disruption of human SOX6 is insufficient to impair erythropoiesis or silencing of fetal hemoglobin. Blood. 2011;117: Arnaud L, Saison C, Helias V, et al. A dominant mutation in the gene encoding the erythroid transcription factor KLF1 causes a congenital dyserythropoietic anemia. Am J Hum Genet. 2010; 87: Satta S, Perseu L, Moi P, et al. Compound heterozygosity for KLF1 mutations associated with remarkable increase of fetal hemoglobin and red cell protoporphyrin. Haematologica. 2011; 96: Wahlberg K, Jiang J, Rooks H, et al. The HBS1L-MYB intergenic interval associated with elevated HbF levels shows characteristics of a distal regulatory region in erythroid cells. Blood. 2009;114: Jiang J, Best S, Menzel S, et al. cmyb is involved in the regulation of fetal hemoglobin production in adults. Blood. 2006;108: Sankaran VG, Menne TF, Scepanovic D, et al. MicroRNA-15a and act via MYB to elevate fetal hemoglobin expression in human trisomy 13. Proc Natl Acad Sci U S A. 2011;108: Zhao H, Kalota A, Jin S, Gewirtz AM. The c-myb protooncogene and microrna-15a comprise an active autoregulatory feedback loop in human hematopoietic cells. Blood. 2009;113: Galarneau G, Palmer CD, Sankaran VG, Orkin SH, Hirschhorn JN, Lettre G. Fine-mapping at three loci known to affect fetal hemoglobin levels explains additional genetic variation. Nat Genet. 2010;42: Carpinelli MR, Hilton DJ, Metcalf D, et al. Suppressor screen in Mpl-/- mice: c-myb mutation causes supraphysiological production of platelets in the absence of thrombopoietin signaling. Proc Natl Acad Sci U S A. 2004;101: van Dijk TB, Gillemans N, Pourfarzad F, et al. Fetal globin expression is regulated by Friend of Prmt1. Blood. 2010;116: Banzon V, Ibanez V, Vaitkus K, et al. sidnmt1 increases gamma-globin expression in chemical inducer of dimerization (CID)-dependent mouse betayac bone marrow cells and in baboon erythroid progenitor cell cultures. Exp Hematol. 2011; 39:26-36 e Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature. 2010;467: Koehler AN. A complex task? Direct modulation of transcription factors. Curr Opin Chem Biol. 2010;14: Boumber Y, Issa JP. Epigenetics in cancer: what s the future? Oncology (Williston Park). 2011;25: , 228. Hematology
CRISPR-mediated Editing of Hematopoietic Stem Cells for the Treatment of β-hemoglobinopathies
CRISPR-mediated Editing of Hematopoietic Stem Cells for the Treatment of β-hemoglobinopathies Jennifer Gori American Society of Gene & Cell Therapy May 11, 2017 editasmedicine.com 1 Highlights Developed
More informationGamma gene expression in haemoglobin disorders
Gamma gene expression in haemoglobin disorders Innovative therapies for Red Cell and Iron related disorders EHA / ESH : April 16-18, Cascais, Portugal Swee Lay Thein King s College London School of Medicine
More informationPreface: Thalassemia Bernard G. Forget
Thalassemia Preface: Thalassemia Bernard G. Forget xiii Thalassemia: An Overview of 50 Years of Clinical Research 1005 Vijay G. Sankaran and David G. Nathan The thalassemias are attributable to the defective
More informationFetal hemoglobin regulation in β-thalassemia: heterogeneity, modifiers and therapeutic approaches
Expert Review of Hematology ISSN: 1747-4086 (Print) 1747-4094 (Online) Journal homepage: http://www.tandfonline.com/loi/ierr20 Fetal hemoglobin regulation in β-thalassemia: heterogeneity, modifiers and
More informationENHANCED production of fetal hemoglobin (a g ) 2 2
1606 THE NEW ENGLAND JOURNAL OF MEDICINE June 15, 1995 EXTENDED THERAPY WITH INTRAVENOUS ARGININE BUTYRATE IN PATIENTS WITH -HEMOGLOBINOPATHIES GRAHAM D. SHER, M.B., B.CH., GORDON D. GINDER, M.D., JANE
More informationGenetic Modulation on the Phenotypic Diversity of Sickle Cell Disease
Genetic Modulation on the Phenotypic Diversity of Sickle Cell Disease Malay B. Mukherjee Abstract Sickle cell hemoglobin is a β chain structural variant where valine is substituted for glutamic acid in
More informationGeorge R. Honig Junius G. Adams III. Human Hemoglobin. Genetics. Springer-Verlag Wien New York
George R. Honig Junius G. Adams III Human Hemoglobin Genetics Springer-Verlag Wien New York George R. Honig, M.D., Ph.D. Professor and Head Department of Pediatrics, College of Medicine University of Illinois
More informationA Functional Element Necessary for Fetal Hemoglobin Silencing
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article A Functional Element Necessary for Fetal Hemoglobin Silencing Vijay G. Sankaran, M.D., Ph.D., Jian Xu, Ph.D., Rachel Byron, B.S.,
More informationGenetic Studies of Human Hematopoiesis
Genetic Studies of Human Hematopoiesis Vijay G. Sankaran, M.D., Ph.D. sankaran@broadinstitute.org @bloodgenes August 23, 2018 SWISSTRANSFUSION 2018 A Perspective on Hematopoiesis Laurenti & Gottgens, Nature,
More informationFetal hemoglobin regulation in β-thalassemia: heterogeneity, modifiers and therapeutic approaches
Expert Review of Hematology ISSN: 1747-4086 (Print) 1747-4094 (Online) Journal homepage: http://www.tandfonline.com/loi/ierr20 Fetal hemoglobin regulation in β-thalassemia: heterogeneity, modifiers and
More informationIn adults, the predominant Hb (HbA) molecule has four chains: two α and two β chains. In thalassemias, the synthesis of either the α or the β chains
Thalassaemias Thalassemia Thalassemia is an inherited autosomal recessive blood disease. Associated with absence or reduction in a or b globin chains. Reduced synthesis of one of the globin chains can
More informationMaking Hope A Reality December 10, Nasdaq : BLUE
Making Hope A Reality December 10, 2014 Nasdaq : BLUE Forward Looking Statement These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words
More informationGenetic Modifiers of Sickle Cell Disease Severity. Kunle Adekile, MD, PhD Professor Department of Pediatrics Kuwait University
Genetic Modifiers of Sickle Cell Disease Severity Kunle Adekile, MD, PhD Professor Department of Pediatrics Kuwait University Outline Hb Molecule and Genetic control of globin synthesis Pathophysiology
More informationGenetic association studies in -hemoglobinopathies
HEMOGLOBINOPATHIES:FRESH IDEAS FOR MANAGEMENT Genetic association studies in -hemoglobinopathies Swee Lay Thein 1 1 Department of Haematological Medicine, King s College Hospital National Health Service
More informationAn overview of Thalassaemias and Complications
An overview of Thalassaemias and Complications Haemoglobin Haemoglobin is the most abundant protein in blood, and exists as three main types in normal adults: HbA ( ) - 97% HbA 2 ( ) - 2.5% HbF ( ) - 0.5%
More informationThe Nucleated Red Blood Cell (NRBC) Count in Thalassaemia Syndromes Paolo Danise and Giovanni Amendola
7. The Nucleated Red The Nucleated Red Blood Cell (NRBC) Count in Thalassaemia Syndromes Paolo Danise and Giovanni Amendola Introduction The purpose of this study was to evaluate the performance of the
More informationThalassemias:general aspects and molecular pathology
Thalassemias:general aspects and molecular pathology Prof. Renzo Galanello Pediatric Clinic 2 University of Cagliari Ospedale Regionale Microcitemie-ASL8 HEMOGLOBINOPATHIES CLASSIFICATION Structurally
More informationThalassemia Maria Luz Uy del Rosario, M.D.
Thalassemia Maria Luz Uy del Rosario, M.D. Philippine Society of Hematology and Blood Transfusion Philippine Society of Pediatric Oncology What is Thalassemia Hereditary Hemoglobin disorder Hemolytic anemia
More informationHaemoglobin BY: MUHAMMAD RADWAN WISSAM MUHAMMAD
Haemoglobin BY: MUHAMMAD RADWAN WISSAM MUHAMMAD Introduction is the iron-containing oxygen transport metalloprotein in the red blood cells Hemoglobin in the blood carries oxygen from the respiratory organs
More informationChanges in hematological parameters in α-thalassemia individuals co-inherited with erythroid Krüppel-like factor mutations
Clin Genet 2015: 88: 56 61 Printed in Singapore. All rights reserved Short Report 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd CLINICAL GENETICS doi: 10.1111/cge.12443 Changes in hematological
More informationTHALASSEMIA AND COMPREHENSIVE CARE
1 THALASSEMIA AND COMPREHENSIVE CARE Melanie Kirby MBBS, FRCP (C), Hospital for Sick Children, Toronto Associate Professor of Paediatrics, University of Toronto. Objectives 2 By the end of this presentation,
More informationEpidemiological Study among Thalassemia Intermedia Pediatric Patients
Med. J. Cairo Univ., Vol. 78, No. 2, December 651-655, 2010 www.medicaljournalofcairouniversity.com Epidemiological Study among Thalassemia Intermedia Pediatric Patients NERMEEN KADDAH, M.D.; KHALED SALAMA,
More informationInternational Journal of Drug Research and Technology
Int. J. Drug Res. Tech. 2012, Vol. 2 (7), 472-478 ISSN 2277-1506 International Journal of Drug Research and Technology Available online at http://www.ijdrt.com Original Research Paper SCREENING, ANALYSIS
More informationSUPPLEMENTARY INFORMATION
doi:10.1038/nature10495 WWW.NATURE.COM/NATURE 1 2 WWW.NATURE.COM/NATURE WWW.NATURE.COM/NATURE 3 4 WWW.NATURE.COM/NATURE WWW.NATURE.COM/NATURE 5 6 WWW.NATURE.COM/NATURE WWW.NATURE.COM/NATURE 7 8 WWW.NATURE.COM/NATURE
More informationFOXO3 Regulates Fetal Hemoglobin Levels in Sickle Cell Anemia. Yankai Zhang, Jacy R. Crosby, Eric Boerwinkle, Vivien A. Sheehan
FOXO3 Regulates Fetal Hemoglobin Levels in Sickle Cell Anemia Yankai Zhang, Jacy R. Crosby, Eric Boerwinkle, Vivien A. Sheehan Sickle Cell Anemia Steinberg MH. N Engl J Med 1999;340:1021-1030. Akinsheye
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/35456 holds various files of this Leiden University dissertation. Author: Hassan, Suha Mustafa Title: Toward prevention of Hemoglobinopathies in Oman Issue
More informationThalassemia. By: Rebecca Chang (Period 6)
+ Thalassemia By: Rebecca Chang (Period 6) + Physiology Ø Two types of thalassemia: alpha and beta Ø Autosomal recessive inheritance pattern Ø Hemoglobin is damaged but symptoms greatly vary, especially
More informationHemolytic anemias (2 of 2)
Hemolytic anemias (2 of 2) Sickle Cell Anemia The most common familial hemolytic anemia in the world Sickle cell anemia is the prototypical (and most prevalent) hemoglobinopathy Mutation in the β-globin
More informationHigh Hemoglobin F in a Saudi Child Presenting with Pancytopenia
Case Report imedpub Journals http://www.imedpub.com Journal of Pediatric Care ISSN 2471-805X DOI: 10.21767/2471-805X.100002 High Hemoglobin F in a Saudi Child Presenting with Pancytopenia Abstract Saudi
More informationAnemia s. Troy Lund MSMS PhD MD
Anemia s Troy Lund MSMS PhD MD lundx072@umn.edu Hemoglobinopathy/Anemia IOM take home points. 1. How do we identify the condtion? Smear, CBC Solubility Test (SCD) 2. How does it present clincally? 3. How
More informationEditorial PRESENT STATUS OF HEMOGLOBINOPATHIES IN INDIA
Editorial PRESENT STATUS OF HEMOGLOBINOPATHIES IN INDIA The last decade has witnessed an enormous progress in the field of hemoglobinopathies. This explosion in knowledge came in the wake of advances in
More informationHydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model
Published Ahead of Print on April 7, 2010, as doi:10.3324/haematol.2010.023325. Copyright 2010 Ferrata Storti Foundation. Early Release Paper Hydroxyurea therapy requires HbF induction for clinical benefit
More informationHU: Myths and Facts. Melanie Kirby Associate Professor of Paediatrics
HU: Myths and Facts Melanie Kirby Associate Professor of Paediatrics SACGO Hamilton, Ontario March 5, 2016 Declaration of Disclosure I have no actual or potential conflict of interest in relation to this
More informationCOHEM Barcellona 2012 Hemoglobinopathies debate
COHEM Barcellona 2012 Hemoglobinopathies debate September 8, 2012: h. 10:30-12:00 Hall: A Is it justified to perform BMT in hemoglobinopathies using unrelated and/or partially mismatched donors? HSCT indication
More informationThe Beats of Natural Sciences Issue 3-4 (September-December) Vol. 3 (2016)
Frequency of β (Beta Thalassaemia) Trait and Haemaglobin E (HbE) Trait: Case Study in a Thalassaemia Carrier Detection Camp in Gurudas College, West Bengal, India Mitu De Department of Botany, Gurudas
More informationToday. Genomic Imprinting & X-Inactivation
Today 1. Quiz (~12 min) 2. Genomic imprinting in mammals 3. X-chromosome inactivation in mammals Note that readings on Dosage Compensation and Genomic Imprinting in Mammals are on our web site. Genomic
More informationHaemoglobinophaties EBMT 2011 Data Manager session
Haemoglobinophaties EBMT 2011 Data Manager session Presentation plan Biological characteristics Clinical characteristics Transplant resuts What is different From transplant in malignancies Between Thalassemia
More informationChapter 7 Conclusions
VII-1 Chapter 7 Conclusions VII-2 The development of cell-based therapies ranging from well-established practices such as bone marrow transplant to next-generation strategies such as adoptive T-cell therapy
More informationSICKLE CELL DISEASE. Dr. MUBARAK ABDELRAHMAN MD PEDIATRICS AND CHILD HEALTH. Assistant Professor FACULTY OF MEDICINE -JAZAN
SICKLE CELL DISEASE Dr. MUBARAK ABDELRAHMAN MD PEDIATRICS AND CHILD HEALTH Assistant Professor FACULTY OF MEDICINE -JAZAN Objective: The student should be able: To identify the presentation, diagnosis,
More informationProkaryotes and eukaryotes alter gene expression in response to their changing environment
Chapter 18 Prokaryotes and eukaryotes alter gene expression in response to their changing environment In multicellular eukaryotes, gene expression regulates development and is responsible for differences
More informationComprehensive Hemoglobin Analysis HBA1/2 (
Comprehensive Hemoglobin Analysis HBA1/2 ( α-globin) and HBB (β-globin) mutation and deletion/duplication analysis and HBD (δ-globin) and HBG1/2 (γ-globin) mutation analysis Description: Hemoglobin (Hb)
More informationBiology 2C03: Genetics What is a Gene?
Biology 2C03: Genetics What is a Gene? September 9 th, 2013 Model Organisms - E. coli - Yeast - Worms - Arabodopsis - Fruitflie - Mouse What is a Gene? - Define, recognize, describe and apply Mendel s
More informationHydroxyurea and Transfusion Therapy for the Treatment of Sickle Cell Disease
Hydroxyurea and Transfusion Therapy for the Treatment of Sickle Cell Disease A Pocket Guide for the Clinician Susan E. Creary, MD, MSc 1 John J. Strouse, MD, PhD 2 1 The Ohio State University School of
More informationDisclosures of: Emanuele Angelucci
Company name Novartis Disclosures of: Emanuele Angelucci Research support Employee Consultant Stockholder Speakers bureau Advisory board Chair of TELESTO pro Other EBMT 2012 Educational Session Haemoglobinopathy
More informationDr Banu Kaya Consultant Haematologist Barts Health NHS Trust Royal London Hospital, London, UK SICKLE CELL AND THALASSAEMIA OVERVIEW
Dr Banu Kaya Consultant Haematologist Barts Health NHS Trust Royal London Hospital, London, UK SICKLE CELL AND THALASSAEMIA OVERVIEW Objectives Gain awareness of haemoglobinopathy inheritance, pathophysiology
More informationQuarterly Update & ASH 2017 Abstract Conference Call
Quarterly Update & ASH 2017 Abstract Conference Call November 1, 2017 Nasdaq : BLUE 1 Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and
More informationDONE BY : RaSHA RAKAN & Bushra Saleem
DONE BY : RaSHA RAKAN & Bushra Saleem Hemolytic anemias (2 of 2) Sickle Cell Anemia The most common familial hemolytic anemia in the world Sickle cell anemia is the prototypical (and most prevalent) hemoglobinopathy
More informationFetal Globin Induction Can It Cure β Thalassemia?
Fetal Globin Induction Can It Cure β Thalassemia? Susan P. Perrine The β thalassemias are one of a few medical conditions in which reactivation of a gene product that is expressed during fetal life can
More informationSupplemental Material for:
Supplemental Material for: Transcriptional silencing of γ-globin by BCL11A involves long-range interactions and cooperation with SOX6 Jian Xu, Vijay G. Sankaran, Min Ni, Tobias F. Menne, Rishi V. Puram,
More informationIncreased fetal hemoglobin levels lessen the severity of symptoms
ARTICLE Red Cell Biology & its Disorders EUROPEAN HEMATOLOGY ASSOCIATION Ferrata Storti Foundation The LSD1 inhibitor RN-1 recapitulates the fetal pattern of hemoglobin synthesis in baboons (P. anubis)
More informationAgro/Ansc/Bio/Gene/Hort 305 Fall, 2017 MEDICAL GENETICS AND CANCER Chpt 24, Genetics by Brooker (lecture outline) #17
Agro/Ansc/Bio/Gene/Hort 305 Fall, 2017 MEDICAL GENETICS AND CANCER Chpt 24, Genetics by Brooker (lecture outline) #17 INTRODUCTION - Our genes underlie every aspect of human health, both in function and
More informationCorporate Medical Policy
Corporate Medical Policy Genetic Testing for Alpha Thalassemia File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_alpha_thalassemia 9/2013 7/2017 7/2018 7/2017 Description
More informationmirna Dr. S Hosseini-Asl
mirna Dr. S Hosseini-Asl 1 2 MicroRNAs (mirnas) are small noncoding RNAs which enhance the cleavage or translational repression of specific mrna with recognition site(s) in the 3 - untranslated region
More informationCh. 18 Regulation of Gene Expression
Ch. 18 Regulation of Gene Expression 1 Human genome has around 23,688 genes (Scientific American 2/2006) Essential Questions: How is transcription regulated? How are genes expressed? 2 Bacteria regulate
More informationThe Effect of Hydroxyurea Treatment on Fetal Haemoglobin Level and Clinical Status of Sudanese Sickle Cell Anaemia Patients
EUROPEAN ACADEMIC RESEARCH Vol. II, Issue 6/ September 2014 ISSN 2286-4822 www.euacademic.org Impact Factor: 3.1 (UIF) DRJI Value: 5.9 (B+) The Effect of Hydroxyurea Treatment on Fetal Haemoglobin Level
More informationIdentification and validation of a new class of HDAC inhibitors able to induce HbF in thalassemic erythroid precursors.
Identification and validation of a new class of HDAC inhibitors able to induce HbF in thalassemic erythroid precursors. Daniela Natale, PhD IRBM Science Park, Pomezia (Rome) ITALY This work was funded
More informationGene Expression DNA RNA. Protein. Metabolites, stress, environment
Gene Expression DNA RNA Protein Metabolites, stress, environment 1 EPIGENETICS The study of alterations in gene function that cannot be explained by changes in DNA sequence. Epigenetic gene regulatory
More informationSeptember 20, Submitted electronically to: Cc: To Whom It May Concern:
History Study (NOT-HL-12-147), p. 1 September 20, 2012 Re: Request for Information (RFI): Building a National Resource to Study Myelodysplastic Syndromes (MDS) The MDS Cohort Natural History Study (NOT-HL-12-147).
More informationGENETIC FACTORS INFLUENCING HEMOGLOBIN
Southeast Asian J Trop Med Public Health GENETIC FACTORS INFLUENCING HEMOGLOBIN F LEVEL IN β-thalassemia/hb E DISEASE Waraporn Ruangrai and Sumalee Jindadamrongwech Department of Pathology, Faculty of
More informationSickle Cell Disease Why Is A Simple Genetic Disorder So Hard To Treat And How Are We Doing?
Sickle Cell Disease Why Is A Simple Genetic Disorder So Hard To Treat And How Are We Doing? James R. Eckman, MD Professor of Medicine, Hematology and Oncology Winship Cancer Institute Emory University
More informationGenetics and Genomics in Medicine Chapter 6 Questions
Genetics and Genomics in Medicine Chapter 6 Questions Multiple Choice Questions Question 6.1 With respect to the interconversion between open and condensed chromatin shown below: Which of the directions
More informationHydroxurea: A Novel Approach to Optimizing the Health of Pediatric Patients with Sickle Cell Disease. Maa Ohui Quarmyne September 9 th, 2017
Hydroxurea: A Novel Approach to Optimizing the Health of Pediatric Patients with Sickle Cell Disease Maa Ohui Quarmyne September 9 th, 2017 Outline Sickle Cell Disease Pathophysiology and Clinical Manifestations
More informationGene Therapy for Sickle Cell Disease: A Safety/Efficacy Trial
Gene Therapy for Sickle Cell Disease: A Safety/Efficacy Trial Elizabeth Hexner A. Introduction Sickle cell disease (SCD) is an autosomal recessive disease of red blood cells (RBCs). A single amino acid
More informationBeta Thalassemia Frequency in Bahrain: A Ten Year Study. Shaikha Salim Al-Arrayed, MB,ChB, DHCG, PhD*
Bahrain Medical Bulletin, Vol. 2, No. 2, June 200 Beta Thalassemia Frequency in Bahrain: A Ten Year Study Shaikha Salim Al-Arrayed, MB,ChB, DHCG, PhD* Background: Sickle-cell disease and Thalassanemia
More informationRegulation of Gene Expression in Eukaryotes
Ch. 19 Regulation of Gene Expression in Eukaryotes BIOL 222 Differential Gene Expression in Eukaryotes Signal Cells in a multicellular eukaryotic organism genetically identical differential gene expression
More informationClinical Policy: Allogenic Hematopoietic Cell Transplants for Sickle Cell Anemia and β-thalassemia
Clinical Policy: Allogenic Hematopoietic Cell Transplants for Sickle Cell Anemia and β-thalassemia Reference Number: CP.MP.108 Effective Date: 03/16 Last Review Date: 03/17 See Important Reminder at the
More informationEpigenetic Principles and Mechanisms Underlying Nervous System Function in Health and Disease Mark F. Mehler MD, FAAN
Epigenetic Principles and Mechanisms Underlying Nervous System Function in Health and Disease Mark F. Mehler MD, FAAN Institute for Brain Disorders and Neural Regeneration F.M. Kirby Program in Neural
More informationEpigenetics. Lyle Armstrong. UJ Taylor & Francis Group. f'ci Garland Science NEW YORK AND LONDON
... Epigenetics Lyle Armstrong f'ci Garland Science UJ Taylor & Francis Group NEW YORK AND LONDON Contents CHAPTER 1 INTRODUCTION TO 3.2 CHROMATIN ARCHITECTURE 21 THE STUDY OF EPIGENETICS 1.1 THE CORE
More informationOverview: Conducting the Genetic Orchestra Prokaryotes and eukaryotes alter gene expression in response to their changing environment
Overview: Conducting the Genetic Orchestra Prokaryotes and eukaryotes alter gene expression in response to their changing environment In multicellular eukaryotes, gene expression regulates development
More informationSickle Cell Anemia. Sickle cell anemia is an inherited disorder of the blood which occurs when just one base pair substitution
Rose Farrington and Rachel Nash BIOL 362 Lab M. Bulgarella Genetic Diseases 10/14/2008 Sickle Cell Anemia Introduction Sickle cell anemia is an inherited disorder of the blood which occurs when just one
More informationFetal Anemia 02/13/13. Anjulika Chawla, M.D. Assistant Professor Division of Pediatric Hematology/Oncology
Fetal Anemia 02/13/13 Anjulika Chawla, M.D. Assistant Professor Division of Pediatric Hematology/Oncology Objectives Definition of anemia Diagnosis of fetal anemia Normal developmental hematopoiesis Etiology
More information4 Fahed Al Karmi Sufian Alhafez Dr nayef karadsheh
4 Fahed Al Karmi Sufian Alhafez Dr nayef karadsheh Genetic variants of hemoglobin Hemoglobinopathies (abnormal variants of hemoglobin) are divided into: 1. Structural abnormalities: Any change in the genes
More informationHEMOGLOBINOPATHIES LECTURE OUTLINE. An overview of the structure of hemoglobin. Different types of hemoglobin. Definition of hemoglobinopathies
Slide 1 HEOGLOBINOPATHIES Slide 2 LETURE OUTLINE An overview of the structure of hemoglobin. Different types of hemoglobin. Definition of hemoglobinopathies Sickle ell Disease and Hemoglobin Slide 3 HEOGLOBIN
More informationJefferies 2015 Global Healthcare Conference Engineering Genetic Cures
Jefferies 2015 Global Healthcare Conference Engineering Genetic Cures Edward Lanphier President and CEO Sangamo BioSciences, Inc. June 1, 2015 Forward Looking Statements This presentation contains forward-looking
More informationSickle cell disease. Fareed Omar 10 March 2018
Sickle cell disease Fareed Omar 10 March 2018 Physiology Haemoglobin structure HbA2: 2α and 2δ chains (2-3%) HbF: 2α and 2γ chains (
More information1 Kattamis et al. Growth of Children with Thalassemia: Effect of Different Transfusion Regimens. Archives of
Objectives Sickle Cell Anemia and Thalassemia: Transplantation Provide overview of hemoglobinopathies: Sickle cell disease and Thalassemia Discuss approaches to therapy Review recent registry collaboration
More informationSupplementary Information. Preferential associations between co-regulated genes reveal a. transcriptional interactome in erythroid cells
Supplementary Information Preferential associations between co-regulated genes reveal a transcriptional interactome in erythroid cells Stefan Schoenfelder, * Tom Sexton, * Lyubomira Chakalova, * Nathan
More informationClassroom Tested Lesson Video Description Secrets of the Sequence, Show 108, Episode 2
Classroom Tested Lesson Video Description Secrets of the Sequence, Show 108, Episode 2 Sickle Cell Anemia Hope from Gene Therapy approximately 10 minutes viewing time This inherited red blood cell disorder
More informationFragile X Syndrome. Genetics, Epigenetics & the Role of Unprogrammed Events in the expression of a Phenotype
Fragile X Syndrome Genetics, Epigenetics & the Role of Unprogrammed Events in the expression of a Phenotype A loss of function of the FMR-1 gene results in severe learning problems, intellectual disability
More informationUtility of hemoglobin electrophoresis to detect hemoglobinopathies in adults not presenting with hematological problems
Original Research Article Utility of hemoglobin electrophoresis to detect hemoglobinopathies in adults not presenting with hematological problems G. J. Vani Padmaja 1*, S. S. S. Quadri 1, O. Shravan Kumar
More informationHemoglobinopathies Diagnosis and management
Hemoglobinopathies Diagnosis and management Morgan L. McLemore, M.D. Hematology/Leukemia Department of Hematology and Oncology Winship Cancer Institute at Emory University mlmclem@emory.edu Disclosures
More information2018 Biochemistry 110 California Institute of Technology Lecture 7: Molecular Disease: Sickle-Cell Anemia
2018 Biochemistry 110 California Institute of Technology Lecture 7: Molecular Disease: Sickle-Cell Anemia James Herrick (1861-1954) Phase-Contrast microscopy image of Sickle Cells intermingled with erythrocytes.
More informationOriginal Research Article Ssafety and efficacy of prolonged hydroxycarbamide administration in adults with
1 1 2 3 Original Research Article Ssafety and efficacy of prolonged hydroxycarbamide administration in adults with sickle cell disease in Northwestern Greece 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
More informationReport of Beta Thalassemia in Newar Ethnicity
Report of Beta Thalassemia in Newar Ethnicity Rajendra Dev Bhatt 1*, Surendra Koju 2, Prabodh Risal 1 Affiliations: 1 Department of Clinical Biochemistry, Dhulikhel Hospital, Kathmandu University Hospital
More informationijifm case report ABSTRACT
ijifm case report 1p36 Deletions 10.5005/jp-journals-10016-1085 in Two Cases with Thalassemia 1p36 Deletions in Two Cases with Thalassemia 1 Puspal De, 2 Sudipa Chakravarty, 3 Amit Chakravarty ABSTRACT
More informationEpigenetics q&more 01.11
Laurie. Knight, istockphoto.com Epigenetics 6 Bookmarks About the reading of genes in the Book of Life Prof. Dr. Manfred Jung, Julia M. Wagner, Institute for Pharmaceutical Sciences, Albert-Ludwig-University
More informationGenetics and Genomics in Medicine Chapter 8 Questions
Genetics and Genomics in Medicine Chapter 8 Questions Linkage Analysis Question Question 8.1 Affected members of the pedigree above have an autosomal dominant disorder, and cytogenetic analyses using conventional
More informationAN INTRODUCTION TO EPIGENETICS DR CHLOE WONG
AN INTRODUCTION TO EPIGENETICS DR CHLOE WONG MRC SGDP CENTRE, INSTITUTE OF PSYCHIATRY KING S COLLEGE LONDON Oct 2015 Lecture Overview WHY WHAT EPIGENETICS IN PSYCHIARTY Technology-driven genomics research
More informationAlpha thalassemia mental retardation X-linked. Acquired alpha-thalassemia myelodysplastic syndrome
Alpha thalassemia mental retardation X-linked Acquired alpha-thalassemia myelodysplastic syndrome (Alpha thalassemia mental retardation X-linked) Acquired alpha-thalassemia myelodysplastic syndrome Schematic
More informationHematological profile among Sudanese patients with sickle cell anemia
EUROPEAN ACADEMIC RESEARCH Vol. III, Issue 4/ July 2015 ISSN 2286-4822 www.euacademic.org Impact Factor: 3.4546 (UIF) DRJI Value: 5.9 (B+) Hematological profile among Sudanese patients with sickle cell
More informationSICKLE CELL DISEASE TO TREAT OR
SICKLE CELL DISEASE TO TREAT OR NOT TO TREAT COHEM Barcelona September 8, 2012 Sujit Sheth, M.D. Pediatric Hematology Oncology Disclosures None Outline Morbidity and mortality Definitive therapies Risk
More informationChapter 2 Genetic Basis and Genetic Modifiers of β-thalassemia and Sickle Cell Disease
Chapter 2 Genetic Basis and Genetic Modifiers of β-thalassemia and Sickle Cell Disease Swee Lay Thein Abstract β-thalassemia and sickle cell disease (SCD) are prototypical Mendelian single gene disorders,
More informationEpigenetics 101. Kevin Sweet, MS, CGC Division of Human Genetics
Epigenetics 101 Kevin Sweet, MS, CGC Division of Human Genetics Learning Objectives 1. Evaluate the genetic code and the role epigenetic modification plays in common complex disease 2. Evaluate the effects
More informationAre you the way you are because of the
EPIGENETICS Are you the way you are because of the It s my fault!! Nurture Genes you inherited from your parents? Nature Experiences during your life? Similar DNA Asthma, Autism, TWINS Bipolar Disorders
More informationChapter 11. How Genes Are Controlled. Lectures by Edward J. Zalisko
Chapter 11 How Genes Are Controlled PowerPoint Lectures for Campbell Essential Biology, Fifth Edition, and Campbell Essential Biology with Physiology, Fourth Edition Eric J. Simon, Jean L. Dickey, and
More informationHAEMOGLOBIN ESTIMATION
HAEMOGLOBIN ESTIMATION STRUCTURE OF HAEMOGLOBIN: Haemoglobin is a chromoprotein consisting of the colourless globin and four red coloured haem molecules. Haemoglobin is a metal complex, containing an
More informationEpidemiology, Care and Prevention of Hemoglobinopathies
Epidemiology, Care and Prevention of Hemoglobinopathies Nasir Al-Allawi MBChB, PhD. Professor of Hematology College of Medicine University of Dohuk, IRAQ From Research to Practice Training Course in Sexual
More informationIntroduction to Genetics
Introduction to Genetics Table of contents Chromosome DNA Protein synthesis Mutation Genetic disorder Relationship between genes and cancer Genetic testing Technical concern 2 All living organisms consist
More information6.1 Extended family screening
CHAPTER 6 CONCLUSION Cost benefit analysis of thalassemia screening programs have shown that the single years treatment for a β-thalassemia major patient was much higher than a total cost per case prevented.
More information